『Beta Finch - Danaher - DHR - EN』のカバーアート

Beta Finch - Danaher - DHR - EN

Beta Finch - Danaher - DHR - EN

著者： Beta Finch
無料で聴く

概要
 AI-powered earnings call analysis for Danaher (DHR). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Danaher Q3 2026 Earnings Analysis

    Danaher Q3 2026 Earnings Analysis
    2026/10/21
    More earnings analysis: https://betafinch.com
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

    **JORDAN:** And I'm Jordan. We've got a big one today — Danaher, ticker DHR, reporting Q3 2026 results, plus a new CEO laying out her vision for the company's "next chapter."

    **ALEX:** Lots to dig into. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Important stuff, now let's get into it. Alex, this quarter actually beat expectations across the board.

    **ALEX:** It did. Revenue came in at $6.6 billion. Core revenue growth, excluding respiratory products, was 5.5% — that's a 100 basis point acceleration from Q2. Adjusted EPS was $2.11, up about 11.5% year-over-year. And free cash flow? $1.6 billion in the quarter alone.

    **JORDAN:** And that cash flow number matters — year-to-date free cash flow to net income conversion was 128%. That's a sign of genuinely high-quality earnings, not just accounting magic.

    **ALEX:** Right. Now, there's a wrinkle here — respiratory diagnostics, think flu and COVID testing, has been a drag all year because infection rates are just lower than prior years. That category was about a 250 basis point headwind in Q3. Strip that out, and the underlying business is clearly reaccelerating.

    **JORDAN:** Segment-wise, Biotechnology grew 5%, with bioprocessing — basically equipment and consumables for manufacturing biologic drugs — coming in at the upper end of mid-single digits. Orders there grew mid-teens, which is a really encouraging forward indicator.

    **ALEX:** Life Sciences grew 4.5%, third straight quarter beating internal expectations. And Diagnostics, excluding respiratory, was up 7%. Beckman Coulter Diagnostics had its best core growth quarter in over two years.

    **JORDAN:** Geographically, high-growth markets were the story — up about 10%, with China up high-single digits across all three segments. Developed markets were basically flat, with North America dragged down mostly by that respiratory decline.

    **ALEX:** On guidance — Danaher raised full-year adjusted EPS guidance to $8.57 to $8.62, up from $8.45 to $8.60. Q4 core growth ex-respiratory is expected at 4% to 5%, with operating margin around 29.5%.

    **JORDAN:** And they gave us an early look at 2027 — suggesting that same 4-5% core growth rate ex-respiratory as a starting point. A few analysts on the call pushed back on that, honestly. Given strong bioprocessing orders, easing China headwinds, and recovering biotech funding, why isn't the number higher?

    **ALEX:** Yeah, that was Tycho Peterson from Jefferies basically saying "show me the acceleration." Management's answer was essentially: we want to get through our Q4 planning process before committing to anything more specific, formal guidance comes in January.

    **JORDAN:** Fair, but it does leave a little tension in the air — is this conservatism, or is something softer under the hood? I'd lean toward conservatism given the order trends they's describing, but it's worth watching.

    **ALEX:** Now let's talk strategy, because this call was really about new CEO Julie Sawyer Montgomery setting her agenda. She's a Danaher veteran — nine years at the company — stepping into the top role for the first time this quarter.

    **JORDAN:** She laid out four priorities: commercial excellence, innovation, talent, and disciplined capital allocation. The headline message was that Danaher's big portfolio transformation — becoming a pure-play Life Sciences and Diagnostics company — is basically done. Now it's about execution and growth, not reshaping the business.

    **ALEX:** The phrase that stuck with me was "unambiguous share gain" — she used it multiple times as the real report card for success going forward.

    **JORDAN

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Coming Soon: Danaher (DHR) Earnings Analysis

    Coming Soon: Danaher (DHR) Earnings Analysis
    2026/10/13
    Beta Finch's AI-powered earnings call analysis for Danaher (DHR) is coming soon. Follow the show to get the first full episode as soon as Danaher reports.

    This episode includes AI-generated content.
    続きを読む 一部表示
    2 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません